经动脉放射性栓塞治疗浸润型肝细胞癌后生存改善
回顾性分析2008至2017年53例浸润型肝细胞癌患者,15例接受经动脉放射性栓塞(TARE),38例接受全身治疗或姑息治疗。TARE组平均总生存16.2个月,对照组5.3个月(Log-rank p<0.0001);Cox回归显示生存与白蛋白、Child-Pugh B级、索拉非尼及受累肝叶数相关。结论认为TARE较舒适治疗或全身治疗可改善浸润型肝细胞癌患者的预期寿命。
要点
- 浸润型肝细胞癌影像表现呈浸润性生长,TARE组平均总生存16.2个月,对照组5.3个月。
- Cox回归显示白蛋白(HR 0.210)、Child-Pugh B级(HR 0.196)、索拉非尼(HR 0.106)及受累肝叶数(HR 1.864)与生存相关。
- 胆红素>3的患者被排除,TARE组与对照组基线资料比较采用Mann-Whitney U检验和Fisher精确检验。
核心结论
- 经动脉放射性栓塞治疗浸润型肝细胞癌较舒适治疗或全身治疗可改善预期寿命。
研究设计与样本
- 回顾性研究,纳入2008至2017年浸润型肝细胞癌患者53例,分为TARE组15例与全身治疗/姑息治疗对照组38例。
- 收集人口学资料、诊断/死亡日期、白蛋白、国际标准化比值(INR)、钠、甲胎蛋白(AFP)、肌酐、Child-Pugh分级、终末期肝病模型(MELD)评分、胆红素、辐射剂量和体积。
- 胆红素>3的患者被排除;采用Mann-Whitney U检验和Fisher精确检验比较组间差异,行Kaplan-Meier生存分析和Cox比例风险分析。
关键影像表现/征象
- 原文描述浸润型肝细胞癌的影像特征,但摘要未报告具体影像征象。
诊断标准与关键数值
- TARE组平均总生存16.2个月,对照组5.3个月(Log-rank p<0.0001)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Infiltrative-appearance hepatocellular carcinoma presents a challenge to clinicians as diagnostic criteria continue to evolve and evidence-based treatment guidelines have yet to be established. While transarterial radioembolization has shown efficacy in hepatocellular carcinoma, many studies exclude infiltrative-appearance HCC in their analysis. The purpose of this study was to describe imaging features of infiltrative-appearance hepatocellular carcinoma and evaluate effects of radioembolization on survival.
METHODS: In a retrospective review, infiltrative HCC patients treated from 2008 to 2017 were identified. Patients were divided into two groups: TARE versus systemic therapy/palliative care. Demographics, dates of diagnosis/expiry, albumin, international normalized ratio (INR), sodium, alpha-fetoprotein (AFP), creatinine, Child-Pugh class, model for end-stage liver disease (MELD) score, bilirubin, radiation dose and volume were collected. Patients with bilirubin > 3 were excluded. Mann-Whitney U test and Fisher's exact test assessed differences between groups. Kaplan-Meier survival and Cox proportional hazard analyses were performed.
RESULTS: Fifty-three patients were identified, 15 underwent TARE while 38 served as control. Mean age was 60, 43 patients were male. The mean overall survival was 16.2 months for the TARE group and 5.3 months for the control group (Log-rank p < 0.0001). Cox proportional regression analysis revealed significant associations between survival and albumin (HR 0.210, 0.052-0.839, p = 0.027), Child-Pugh class B (HR 0.196, 0.055-0.696, p = 0.012), sorafenib (HR 0.106, 0.031-0.360, p < 0.001), and number of affected liver lobes (HR 1.864, 1.387-2.506, p < 0.001).
CONCLUSIONS: Transarterial radioembolization for infiltrative HCC improves life expectancy compared to treatment with comfort measures or systemic therapy.
引用
- Nisiewicz MJ, Kapoor H, Fowler KJ, et al. Improved survival following transarterial radioembolization of infiltrative-appearance hepatocellular carcinoma. Abdom Radiol (NY). 2021. PMID: 33385248. doi:10.1007/s00261-020-02870-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。